Zhu Yiran, Xu Fan, Chen Hao, Zheng Quanhui
School of Basic Medical Sciences, North China University of Science and Technology, Tangshan, China.
Hebei Key Laboratory for Chronic Diseases, Tangshan Key Laboratory for Preclinical and Basic Research on Chronic Diseases, School of Basic Medical Sciences, North China University of Science and Technology, Tangshan, China.
Front Med (Lausanne). 2024 Sep 6;11:1448626. doi: 10.3389/fmed.2024.1448626. eCollection 2024.
It has been reported that the imbalance of gut microbiota is involved in the pathogenesis of psoriasis. We retrieved randomized placebo-controlled trials to evaluate the efficacy and safety of probiotic administration in the treatment of psoriasis.
The outcomes were changes in Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI), and serum inflammatory indicators after treatment, and adverse events (AEs). Risk ratios (RRs) and mean differences (MDs) were calculated using random or fixed effects model.
Seven qualified studies were identified in our study. The pooled percentage of patients with ≥75% reduction from baseline in PASI was higher in the probiotic group than that in the placebo group (33.57% vs. 23.61%; RR 1.40, 95% CI 0.98-1.98, = 0.06). Compared with the placebo group, the PASI (MD -3.09, 95% CI -5.04 to -0.74, = 0.01) and CRP level (MD -2.36, 95% CI -2.77 to -1.95, < 0.0001) were significantly reduced in the probiotic group. There was no significant difference in DLQI (MD -1.45, 95% CI -6.72 to 3.82, = 0.59) and AEs (RR 0.68, 95% CI 0.37-1.25, = 0.22) between the two groups.
Oral administration of probiotics can improve psoriasis; however, large randomized controlled trials are needed to support this conclusion.
PROSPERO, identifier CRD42024506286, https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024506286.
据报道，肠道微生物群失衡参与了银屑病的发病机制。我们检索了随机安慰剂对照试验，以评估益生菌给药治疗银屑病的疗效和安全性。
观察指标为治疗后银屑病面积和严重程度指数（PASI）、皮肤病生活质量指数（DLQI）以及血清炎症指标的变化，还有不良事件（AE）。采用随机或固定效应模型计算风险比（RR）和平均差（MD）。
我们的研究共纳入7项合格研究。益生菌组中PASI较基线降低≥75%的患者合并百分比高于安慰剂组（33.57%对23.61%；RR 1.40，95%CI 0.98 - 1.98，P = 0.06）。与安慰剂组相比，益生菌组的PASI（MD -3.09，95%CI -5.04至 -0.74，P = 0.01）和CRP水平（MD -2.36，95%CI -2.77至 -1.95，P < 0.0001）显著降低。两组之间DLQI（MD -1.45，95%CI -6.72至3.82，P = 0.59）和AE（RR 0.68，95%CI 0.37 - 1.25，P = 0.22）无显著差异。
口服益生菌可改善银屑病；然而，需要大型随机对照试验来支持这一结论。
PROSPERO，标识符CRD42024506286，https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024506286 。
